Signant Health acquired fellow trial data specialist DSG for an undisclosed price as part of its plans to expand service offerings for site-based and decentralized clinical studies.
Pennsylvania-headquartered Signant was attracted to DSG’s platform due to its ease of use, efficiency, flexibility and customer satisfaction, the company said in a July 17 press release.
“DSG’s unified platform, including a full-featured EDC/DDC solution, is an important component in our strategy to offer full, end-to-end capabilities to truly digitalize clinical trials, and offer site-friendly solutions to support all levels of trial decentralization,” Signant CEO Roger Smith said in the release.
Signant has been ramping up its services in the past few years as the industry quickly adopted virtual and decentralized clinical trials in the wake of disruptions caused by the COVID-19 pandemic.
In late 2020, Signant acquired VirTrial and its software solutions package for remote site startup and decentralized clinical trial conduct. That deal allowed Signant to boost its telemedicine platform.